KLA Corporation CapEx decreased by 4.5% to $95.89M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 58.8%, from $60.39M to $95.89M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 9.7% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $55.38M | $68.96M | $109.04M | $56.17M | $73.16M | $84.35M | $60.49M | $118.06M | $78.68M | $68.05M | $84.67M | $63.92M | $60.75M | $60.39M | $141.08M | $33.38M | $100.41M | $95.89M |
| QoQ Change | — | +24.5% | +58.1% | -48.5% | +30.3% | +15.3% | -28.3% | +95.2% | -33.4% | -13.5% | +24.4% | -24.5% | -5.0% | -0.6% | +133.6% | -76.3% | +200.8% | -4.5% |
| YoY Change | — | — | — | — | +32.1% | +22.3% | -44.5% | +110.2% | +7.5% | -19.3% | +40.0% | -45.9% | -22.8% | -11.2% | +66.6% | -47.8% | +65.3% | +58.8% |